Actagardin
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
{{Chembox | ImageFile = Gardimycin.svg | ImageSize = 250px | ImageAlt = | SystematicName = (2R,5S,8R,11S,14S,17R,23R,26R,32R,35S,38R,41R,44R)-44- {(2S,3S)-2-[(2R)-2-{(2S)-2-[(2R)-2-Aminopropanamido]-4-methylpentanamido}butanamido]-3-methylpentanamido}-11-[(2S)-butan-2-yl]-17,41-diethyl-26-(hydroxymethyl)-32-[(1H-indol-3-yl)methyl]-2,5,8,23,38-pentamethyl-4,7,10,13,16,19,22,25,28,31,34,38,40,43-tetradecaoxo-14,35-di(propan-2-yl)-3,6,9,12,15,18,21,24,27,30,33,37,39,42-tetradecaazaheptatetracontanedioic acid | OtherNames = Gardimycin |Section1= |Section2= |Section3= }} Actagardin (INN; also known as gardimycin) is a tetracyclic peptide lantibiotic made by Actinoplanes brasiliensis.
How it works
It was discovered in 1975 by Lepetit S.p.A. Its method of antibiotic activity involves the inhibition of peptidoglycan, preferentially targeting gram negative bacteria. It has become the subject of recent renewed inteterst in the fight against antibiotic resistant bacteria, particularly in the treatment of Streptococcus and Clostridioides difficile , though no pharmaceutical manufacturer is currently known to be pursuing commercialization.
{{Chembox | ImageFile = Gardimycin.svg | ImageSize = 250px | ImageAlt = | SystematicName = (2R,5S,8R,11S,14S,17R,23R,26R,32R,35S,38R,41R,44R)-44- {(2S,3S)-2-[(2R)-2-{(2S)-2-[(2R)-2-Aminopropanamido]-4-methylpentanamido}butanamido]-3-methylpentanamido}-11-[(2S)-butan-2-yl]-17,41-diethyl-26-(hydroxymethyl)-32-[(1H-indol-3-yl)methyl]-2,5,8,23,38-pentamethyl-4,7,10,13,16,19,22,25,28,31,34,38,40,43-tetradecaoxo-14,35-di(propan-2-yl)-3,6,9,12,15,18,21,24,27,30,33,37,39,42-tetradecaazaheptatetracontanedioic acid | OtherNames = Gardimycin |Section1= |Section2= |Section3= }} Actagardin (INN; also known as gardimycin) is a tetracyclic peptide lantibiotic made by Actinoplanes brasiliensis.
It was discovered in 1975 by Lepetit S.p.A. Its method of antibiotic activity involves the inhibition of peptidoglycan, preferentially targeting gram negative bacteria. It has become the subject of recent renewed inteterst in the fight against antibiotic resistant bacteria, particularly in the treatment of Streptococcus and Clostridioides difficile , though no pharmaceutical manufacturer is currently known to be pursuing commercialization.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1367514832 under CC BY-SA 4.0; modifications have been made.